Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection

Taispeáin leaganacha eile (1)

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Reith, C, Staplin, N, Herrington, W, Stevens, W, Emberson, J, Haynes, R, Mafham, M, Armitage, J, Cass, A, Craig, J, Jiang, L, Pedersen, T, Baigent, C, Landray, M, on behalf of the SHARP Collaborative Group
Formáid:	Journal article
Foilsithe / Cruthaithe:	BioMed Central 2017

Míreanna comhchosúla

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
de réir: C. Reith, et al.
Foilsithe / Cruthaithe: (2017-05-01)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
de réir: Storey, B, et al.
Foilsithe / Cruthaithe: (2017)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
de réir: Mihaylova, B, et al.
Foilsithe / Cruthaithe: (2019)

The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
de réir: Herrington, W, et al.
Foilsithe / Cruthaithe: (2014)

Effects of lowering LDL cholesterol on progression of kidney disease.
de réir: Haynes, R, et al.
Foilsithe / Cruthaithe: (2014)

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
de réir: Cholesterol Treatment Trialists' Collaboration, et al.
Foilsithe / Cruthaithe: (2016)

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
de réir: Staplin, N, et al.
Foilsithe / Cruthaithe: (2016)

Evidence for the prevention and treatment of stroke in dialysis patients
de réir: Herrington, W, et al.
Foilsithe / Cruthaithe: (2014)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
de réir: Mafham, M, et al.
Foilsithe / Cruthaithe: (2017)

Benefits of lowering cholesterol in chronic kidney disease Reply
de réir: Baigent, C, et al.
Foilsithe / Cruthaithe: (2011)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
de réir: Zhu, P, et al.
Foilsithe / Cruthaithe: (2020)

Comparison of the accuracy and completeness of records of serious vascular events in routinely collected data vs clinical trial–adjudicated direct follow-up data in the UK: secondary analysis of the ascend randomized clinical trial
de réir: Harper, C, et al.
Foilsithe / Cruthaithe: (2021)

Smoking and adverse outcomes in patients With CKD: the Study of Heart and Renal Protection (SHARP)
de réir: Emberson, J, et al.
Foilsithe / Cruthaithe: (2016)

Efficacy and safety of more intensive lowering of LDL cholesterol Reply
de réir: Baigent, C, et al.
Foilsithe / Cruthaithe: (2011)

Efficacy and safety of more intensive lowering of LDL cholesterol Reply
de réir: Baigent, C, et al.
Foilsithe / Cruthaithe: (2011)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
de réir: Zhu, P, et al.
Foilsithe / Cruthaithe: (2020)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
de réir: Herrington, W, et al.
Foilsithe / Cruthaithe: (2016)

Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis.
de réir: Mafham, M, et al.
Foilsithe / Cruthaithe: (2011)

Reliability of major bleeding events in UK routine data vs clinical trial adjudicated follow-up data
de réir: Harper, C, et al.
Foilsithe / Cruthaithe: (2023)

Comparison of routinely collected data with clinical trial adjudicated direct follow-up: post-hoc analyses of serious cardiovascular events from the United Kingdom-based ASCEND randomized trial
de réir: Harper, C, et al.
Foilsithe / Cruthaithe: (2021)

Impact of CKD on household income
de réir: Morton, R, et al.
Foilsithe / Cruthaithe: (2017)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
de réir: Herrington, WG, et al.
Foilsithe / Cruthaithe: (2023)

Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men.
de réir: Emberson, JR, et al.
Foilsithe / Cruthaithe: (2010)

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).
de réir: Haynes, R, et al.
Foilsithe / Cruthaithe: (2014)

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)
de réir: Haynes, R, et al.
Foilsithe / Cruthaithe: (2014)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
de réir: Haynes, R, et al.
Foilsithe / Cruthaithe: (2018)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
de réir: Herrington, W, et al.
Foilsithe / Cruthaithe: (2022)

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
de réir: Lamprea-Montealegre, J, et al.
Foilsithe / Cruthaithe: (2019)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
de réir: Staplin, N, et al.
Foilsithe / Cruthaithe: (2015)

Conventional and genetic evidence on the association between adiposity and CKD
de réir: Zhu, P, et al.
Foilsithe / Cruthaithe: (2020)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
de réir: Staplin, N, et al.
Foilsithe / Cruthaithe: (2023)

LDL cholesterol targets--how low to go?
de réir: Bulbulia, R, et al.
Foilsithe / Cruthaithe: (2012)

Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
de réir: Baigent, C, et al.
Foilsithe / Cruthaithe: (2010)

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
de réir: Baigent, C, et al.
Foilsithe / Cruthaithe: (2010)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
de réir: Storey, B, et al.
Foilsithe / Cruthaithe: (2018)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
de réir: Baigent, C, et al.
Foilsithe / Cruthaithe: (2011)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
de réir: Baigent, C, et al.
Foilsithe / Cruthaithe: (2011)

Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy.
de réir: Emberson, J, et al.
Foilsithe / Cruthaithe: (2012)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
de réir: Staplin, N, et al.
Foilsithe / Cruthaithe: (2021)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
de réir: Schlackow, I, et al.
Foilsithe / Cruthaithe: (2017)